Search

The success story of plant-based medicine has been overlooked during the advent of the modern pharmaceutical industry. Despite the negligence of the multibillion-dollar drug industry, people entirely rely on medicinal plants in some parts of the world. In this study, we have emphasized going back to those traditional medicinal practices to determine their underlying mechanism to move forward on phytochemical-based drug development. We screened Medicinal Plant Database Bangladesh (MPDB2.0) to find traditionally used medicinal plants and their active compounds.Here, mangiferin, extracted from Mangifera indica, has interacted with cell cycle regulator Cyclin-dependent Kinase 4 (CDK4). CDK4 is differentially expressed during Glioblastoma multiforme (GBM), Brain Lower Grade Glioma (LGG), and Sarcoma (SARC). Expression of CDK4 is interlinked to the patients’ survival rate and its consistent expression throughout different stages has provided the advantage to use it as a diagnostic tool and drug target.This study demonstrated that a simple mango tree extracted active compound ‘mangiferin’ may work as a potential anticancer drug, and leveraging the recent advancement of sequencing and gene expression data can accelerate the phytochemical-based drug discovery process.

Background: Malignancy is one of the prime global causes of mortality. Cancer Patients suffering from SARS-CoV-2 have demonstrated higher rates of severe complications exacerbating towards death. Possible genetic and epigenetic alterations may exist in cancer patients which have the potential to contribute towards their increased vulnerability towards COVID-19. Method: An exhaustive literature search using ‘COVID-19′, ‘SARS-CoV-2′, ‘Cancer’, ‘Malignancy’, ‘Relationships’, Interlinks’, ‘Genetic’, ‘Epigenetic’, ‘Epidemiological studies’, ‘Clinical Studies’, ‘Vaccination’, ‘Vaccine scenario’ were conducted in PubMed and EMBASE till 2nd June 2021. Result: In this narrative review, 17 epidemiological studies were listed which focused on clinical parameters of several malignancy patient cohorts who contracted COVID-19. Besides, genetic and epigenetic alterations seen among cancer patients are also discussed which may plausibly increase the vulnerability of cancer patients to SARS-CoV-2 infection. Also, global vaccination scenario among malignant patients along with the necessity to prioritize them in the vaccination campaigns are also elaborated. Conclusion: Genetic and epigenetic modifications present in ACE2, TMPRSS2, IL-6 and several cytokines require more in-depth research to elucidate the shared mechanisms of malignancy and SARS-CoV-2.